Eikon Therapeutics Closes $148 Million Series A Financing To Develop High-Throughput, Super-Resolution Microscopy For Drug Discovery
Eikon Therapeutics Closes $148 Million Series A Financing To Develop High-Throughput, Super-Resolution Microscopy For Drug Discovery
05/05/21, 10:46 AM
Location
haywardMoney raised
$148 million
Industry
health care
Round Type
series a
Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. The company also announced the appointment of Roger M. Perlmutter, MD, PhD, as its new Chief Executive Officer.
Company Info
Location
hayward, california, united states
Additional Info
Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn.